TIGERMED

3347
35.2804.18% ( -1.540 )
Delay Closed: Nov 16, 16:08:11

Overview

TIGERMED (3347)

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and in...

Open
36.300
High
37.520
Low
33.920
Prev. Close
36.820
Volume
1.83M
Turnover
63.93M
Avg Price
35.009
Bid/Ask Ratio
-80.28%
Amplitude
9.78%
52wk High
56.855
Volume Ratio
0.74
Turnover Ratio
1.48%
52wk Low
27.975
HK Mkt Cap
4.34B
Market CapHKD
30.17B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.551
EPSDynamic
-0.494
EPSStatic
--
BVPS
26.75
P/B
1.32
HK Shares
123.12M
Dividend YieldTTM
0.41%
DividendTTM
0.146
Shares
855.14M
Min lot size
100
Currency
HKD

TIGERMED Analyst Rating

View more

Forecast & Rating

Nov 2, 2026
Price forecast
HK$51.4645.87%
Forecast & RatingBuy
12analysts
  • Strong buy66.67%
  • Buy8.33%
  • Hold25.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Tigermed fell 4.18% to HK$35.28 after a gap-down and spike-and-fade morning, then rebound off HK$34.08 at 13:01 BJ, having touched HK$36.36 at the open. The drag is earnings-side: Q3 revenue rose 25.64% YoY to HK$2.44bn and operating income climbed 59.28% to HK$307.7m, yet net profit fell 76.29% to HK$165.1m and EPS dropped 75.15% to HK$0.1992, leaving a RMB272m nine-month loss; Morgan Stanley cut its target price to RMB53 after the results. Frontage is set to be taken private in a US$616m deal backed by Charles River alongside the sale of its overseas laboratory business, while Goldman Sachs flagged strong Q3 orders for China CRO/CDMO as improving 2027 visibility. At HK$35.28 the stock sits 38.11% below its 52-week high of HK$57, down 16.87% YTD and under both MA20 (HK$38.56) and MA60 (HK$41.51), though revenue and operating profit growth contrast with the profit decline.

  2. Nov, 6

    Tigermed fell 5.15% to HK$39.08 on HK$90.95 million turnover, opening at HK$39.10, spiking to HK$39.96 at 10:01 BJ before sliding to a HK$38.32 low at 09:37 BJ and settling near HK$38.92 in the afternoon — a gap-down-then-fade pattern driven by a 77.9% year-on-year drop in third-quarter net profit and a RMB272 million net loss attributable to shareholders for the first three quarters, reversing from profit a year earlier. Revenue is repairing: Q3 revenue of HK$2.44 billion rose 25.64% and operating profit of HK$308 million rose 59.28%, yet a 6.77% net margin and EPS of HK$0.1992 (down 75.15%) show the earnings-versus-revenue divergence behind the selling. The stock trades below both MA20 (HK$39.99) and MA60 (HK$41.80), down 7.92% year to date and 31.44% below its February 9 high of HK$57, though still 38.98% above the June 8 low of HK$28.12, with negative PE and PB of 1.46. JPMorgan added about 343,200 shares near HK$37.64, while the actual controllers were fined RMB1 million over a seven-year disclosure delay.

  3. Nov, 4

    Tigermed (3347.HK) opened lower but closed up 6.39% at HK$40.28, ranging from HK$37.18 to HK$40.50 as JPMorgan added about 343,200 shares at HK$37.64, CXO names traded actively and Frontage halted on a potential takeover. Third-quarter revenue rose 25.64% year on year to HK$2.438 billion and operating profit increased 59.28% to HK$307.7 million, yet net profit fell 76.29% to HK$165.1 million, EPS dropped 75.15% to HK$0.1992, and the first three quarters showed a net loss attributable to shareholders of RMB272 million, leaving PE at -73.08 alongside PB of 1.51. The stock remains below its 20-day MA of HK$40.46 and 60-day MA of HK$41.83, is down 5.09% year to date, 29.33% below the HK$57 52-week high and 43.24% above the HK$28.12 low. Though a RMB1 million fine on the actual controllers for delayed disclosure still weighs on the earnings-recovery narrative.

  4. Oct, 22

    Tigermed fell 7.63% to HK$38.00, spiking to HK$41.78 at the open before sliding to a HK$37.66 afternoon low, as Hong Kong CXO names weakened through the afternoon and peers lost over 10 percent, while its subsidiary Frontage faces a trading halt over a potential takeover. Q2 revenue rose 19.15% YoY to HK$2.20bn and operating profit gained 25.77%, yet the net loss reached HK$533.9m (-323.62% YoY), with net margin at -24.25% and EPS of -HK$0.5905. The stock sits 33.33% below its 52-week high of HK$57, down 10.46% year-to-date and beneath both its MA20 of HK$43.90 and MA60 of HK$41.87. Though JPMorgan recently added about 235,700 shares at roughly HK$41.45 and Goldman Sachs lifted its Q3 growth view for mainland CRO/CDMO names with average targets up 9%, chairman Ye Xiaoping and fellow directors were fined RMB 500,000 each over disclosure breaches.

  5. Oct, 16

    Tigermed staged a spike-and-fade session, touching HK$43.30 in the morning before sliding to HK$39.28 at 14:43 BJ and closing at HK$40.20 on 1.6779 million shares, as broad weakness across CXO names, Genscript Bio foremost among them, weighed on sentiment. That price action sits awkwardly against fundamentals: Q2 2026 revenue rose 19.15% year on year to HK$2.20 billion, yet net profit swung to a HK$533.9 million loss, down 323.62%, with net margin at -24.25%, while Goldman Sachs still expects mainland CRO and CDMO names to sustain growth in Q3 and lifted its average target price by 9%. The close leaves the stock below both its 20-day moving average of HK$44.825 and its 60-day average of HK$41.745, down 5.28% year to date and 29.47% below its February 9 high of HK$57, though the company had bought back 20.9635 million A-shares by end-September.

News

Bullish vs. Bearish — Last 3 Months

4.0k followers · 0 opinions
▲Bullish50%
50%Bearish▼